ARQT
Arcutis Biotherapeutics, Inc.
NMS
$24.38
-0.21
(-0.85%)
Extended · +1.97σ
Grade B
Quarterly financials
last 5 quarters| Quarter | Revenue | Gross profit | Op income | Net income | Free cash flow | Gross % | Op % | Net % |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $105.4M | $95.6M | $-9.1M | $-11.3M | $2.2M | 90.7% | -8.6% | -10.7% |
| 2025-12-31 | $129.5M | $117.8M | $18.4M | $17.4M | $26.2M | 91.0% | 14.2% | 13.4% |
| 2025-09-30 | $99.2M | $90.5M | $8.5M | $7.4M | $-1.8M | 91.2% | 8.6% | 7.5% |
| 2025-06-30 | $81.5M | $74.0M | $-14.6M | $-15.9M | $-9.8M | 90.8% | -17.9% | -19.5% |
| 2025-03-31 | $65.8M | $57.0M | $-24.5M | $-25.1M | $-31.0M | 86.6% | -37.3% | -38.1% |